<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="481">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05154890</url>
  </required_header>
  <id_info>
    <org_study_id>CACN00177-100D</org_study_id>
    <secondary_id>2019-004791-19</secondary_id>
    <nct_id>NCT05154890</nct_id>
  </id_info>
  <brief_title>A Multiple Ascending Dose Study of ACN00177 in Subjects With CBS Deficiency</brief_title>
  <official_title>A Phase 1/2 Multiple Ascending-Dose Study in Subjects With Homocystinuria Due to Cystathionine β-Synthase (CBS) Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of ACN00177</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aeglea Biotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aeglea Biotherapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of ACN00177 in up to 25&#xD;
      subjects with homocystinuria due to CBS deficiency.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this Phase 1/2 study is to evaluate the safety, pharmacokinetics and&#xD;
      pharmacodynamics of multiple ascending doses of ACN00177 in subjects with homocystinuria due&#xD;
      to CBS deficiency. The study is composed of 2 parts: Part 1: a single IV intravenous) cohort&#xD;
      with 4 once-weekly (QW) doses of study drug and Part 2: three SC (subcutaneous) cohorts with&#xD;
      4 QW doses of study drug.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Reporting will be from signing consent through study completion, an average of 70 days</time_frame>
    <description>Incidence of treatment-emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of IV ACN00177</measure>
    <time_frame>At pre-dose, 1hour, 6hours, 24hours, 48hours, 72hours, 96hours and 120hours</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of IV ACN00177</measure>
    <time_frame>At pre-dose, 1hour, 6hours, 24hours, 48hours, 72hours, 96hours and 120hours</time_frame>
    <description>AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of IV ACN00177</measure>
    <time_frame>At pre-dose, 1hour, 6hours, 24hours, 48hours, 72hours, 96hours and 120hours</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of IV ACN00177</measure>
    <time_frame>At pre-dose, 1hour, 6hours, 24hours, 48hours, 72hours, 96hours and 120hours</time_frame>
    <description>T1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of Subcutaneous ACN00177</measure>
    <time_frame>At pre-dose, 1hour, 6hours, 24hours, 48hours, 72hours, 96hours and 120hours</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of Subcutaneous ACN00177</measure>
    <time_frame>At pre-dose, 1hour, 6hours, 24hours, 48hours, 72hours, 96hours and 120hours</time_frame>
    <description>AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of Subcutaneous ACN00177</measure>
    <time_frame>At pre-dose, 1hour, 6hours, 24hours, 48hours, 72hours, 96hours and 120hours</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of Subcutaneous ACN00177</measure>
    <time_frame>At pre-dose, 1hour, 6hours, 24hours, 48hours, 72hours, 96hours and 120hours</time_frame>
    <description>T1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in total plasma homocysteine after treatment with ACN00177</measure>
    <time_frame>At Visit Day 29</time_frame>
    <description>Changes in total plasma homocysteine after treatment with ACN00177</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of tHcy change after ACN00177 administration and reversibility upon follow up post dosing</measure>
    <time_frame>Weekly, baseline through follow-up for a total of 7 occurrences</time_frame>
    <description>Time course of tHcy change after ACN00177 administration and reversibility upon follow up post dosing</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Homocystinuria Due to Cystathionine Beta-Synthase Deficiency</condition>
  <arm_group>
    <arm_group_label>ACN00177 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Planned for 4 subjects ≥18 years of age dosing at Dose A weekly for a total of 4 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACN00177 Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Planned for 4 subjects ≥12 years of age dosing at Dose B weekly for a total of 4 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACN00177 Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Planned for 4 subjects ≥12 years of age dosing at Dose C weekly for a total of 4 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACN00177 Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Planned for 4 subjects ≥12 years of age dosing at Dose D weekly for a total of 4 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACN00177 Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optional cohort for 4 subjects ≥12 years of age dosing at Dose E weekly for a total of 4 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACN00177</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>ACN00177 Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACN00177</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>ACN00177 Cohort 2</arm_group_label>
    <arm_group_label>ACN00177 Cohort 3</arm_group_label>
    <arm_group_label>ACN00177 Cohort 4</arm_group_label>
    <arm_group_label>ACN00177 Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of homocystinuria due to CBS deficiency&#xD;
&#xD;
          2. Capable of providing signed informed consent/assent and to comply with all study&#xD;
             related procedures&#xD;
&#xD;
          3. Is ≥12 years of age at the time of signing the informed consent/assent&#xD;
&#xD;
          4. Plasma tHcy &gt;80 µM&#xD;
&#xD;
          5. Female subjects of child-bearing potential must have a negative serum pregnancy test&#xD;
             during the screening period and a negative urine pregnancy test prior to dosing on the&#xD;
             first day of treatment&#xD;
&#xD;
          6. If the subject (male or female) is engaging in sexual activity, he/she must be unable&#xD;
             to become pregnant/cause pregnancy or must agree to use highly effective contraception&#xD;
&#xD;
          7. Willing to maintain a stable diet with no significant modifications while on study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other medical conditions or co-morbidity(ies) that, in the opinion of the&#xD;
             investigator, would interfere with study compliance or data interpretation (eg, severe&#xD;
             intellectual disability that precludes completion of the required study assessments)&#xD;
&#xD;
          2. Currently participating in another therapeutic clinical study or has received any&#xD;
             investigational agent within 30 days or 5 half-lives, whichever is longer, prior to&#xD;
             the first dose of study drug in this study&#xD;
&#xD;
          3. Surgery requiring general anesthesia within 8 weeks prior to the first dose of study&#xD;
             drug&#xD;
&#xD;
          4. Active infection requiring anti-infective therapy &lt;2 weeks prior to the first dose of&#xD;
             study drug in this study; anti-infective therapy that completes ≥2 weeks prior to&#xD;
             first dose of study drug is acceptable&#xD;
&#xD;
          5. Pregnant or nursing&#xD;
&#xD;
          6. Females of child-bearing potential who are using or plan to use estrogen-containing&#xD;
             contraception during the study&#xD;
&#xD;
          7. History of hypersensitivity to polyethylene glycol (PEG) that, in the judgment of the&#xD;
             investigator, puts the subject at unacceptable risk for adverse events (AEs)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reena Sharma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Salford Royal NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aeglea Clinical Department</last_name>
    <phone>1.855.509.9921</phone>
    <email>clinicaltrials@aegleabio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Josie Gayton</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Tchan, FRACP</last_name>
    </contact>
    <investigator>
      <last_name>Michel Tchan, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Dawson</last_name>
    </contact>
    <investigator>
      <last_name>Charlotte Dawson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radha Ramachandran</last_name>
    </contact>
    <investigator>
      <last_name>Radha Ramachandran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elaine Murphy, MB</last_name>
    </contact>
    <investigator>
      <last_name>Elaine Murphy, MB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 20, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Homocystinuria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

